Abstract: Provided are an aptamer bound to chymase to inhibit activity of chymase; an aptamer containing a nucleotide sequence represented by X1GAUAGAN1N2UAAX2 wherein X1 and X2 are the same or different and each is A or G, and N1 and N2 are the same or different and each is A, G, C, U or T; a complex containing the aptamer and a functional substance (e.g., affinity substance, labeling substance, enzyme, drug delivery medium, drug and the like); a pharmaceutical or a reagent containing the aptamer or complex; a detection and a purification methods of chymase using the aptamer or complex and the like.

Abstract: Provided are an aptamer having an inhibitory activity on FGF2; a complex containing an aptamer having a binding activity or an inhibitory activity on FGF2, and a functional substance (e.g., affinity substance, labeling substance, enzyme, drug delivery vehicle, or drug and the like); a medicament, diagnostic reagent or label containing an aptamer having a binding activity or an inhibitory activity on FGF2, or a complex containing said aptamer and a functional substance; and the like.

Abstract: The inventors examined the role of MK in experimental autoimmune encephalomyelitis, which is a human model for multiple sclerosis. As a result, they discovered that MK has the effect of inhibiting regulatory T cells, and that the autoimmune mechanism induced by type 1 helper T cells can be suppressed by inhibiting MK expression or its activity, thereby increasing the number of regulatory T cells. Furthermore, it was found that diseases associated with the functional disorder of regulatory T cells can be treated with the administration of an inhibitor that inhibits MK expression or activity.

Abstract: The present invention provides a novel aptamer for IgG and a method for utilizing the same and the like. More specifically, the present invention provides an aptamer that binds to an Fc region of IgG (e.g., human IgG); a complex comprising an aptamer and a functional substance bound thereto (e.g., affinity substance, labeling substance, enzyme, drug, toxin, drug delivery vehicle); a solid phase carrier with an aptamer or complex immobilized thereon; medical equipment comprising a solid phase carrier; a method for antibody purification comprising adsorbing an IgG antibody to a solid phase carrier, and eluting the adsorbed IgG antibody with an eluent; a method for producing a purified antibody, comprising preparing an IgG antibody and purifying the prepared IgG antibody with a solid phase carrier and the like.

Abstract: The inventors examined the role of MK in experimental autoimmune encephalomyelitis, which is a human model for multiple sclerosis. As a result, they discovered that MK has the effect of inhibiting regulatory T cells, and that the autoimmune mechanism induced by type 1 helper T cells can be suppressed by inhibiting MK expression or its activity, thereby increasing the number of regulatory T cells. Furthermore, it was found that diseases associated with the functional disorder of regulatory T cells can be treated with the administration of an inhibitor that inhibits MK expression or activity.

Abstract: Provided is a high-quality aptamer against midkine. An aptamer possessing an inhibitory activity against midkine; a complex comprising an aptamer possessing a binding activity or inhibitory activity against midkine and a functional substance (for example, affinity substances, substances for labeling, enzymes, drug delivery vehicles, drugs and the like); a pharmaceutical drug, cell migration inhibitor, diagnostic reagent, labeling agent and the like comprising an aptamer possessing a binding activity or inhibitory activity against midkine, or a complex comprising the aptamer and a functional substance; a cell migration inhibitor, a diagnostic reagent, a labeling agent and the like.